Skip to main content
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. — Investor Relations & Filings

Ticker · ORKA ISIN · US6876041087 US Manufacturing
Open in API
Filings indexed 997 across all filing types
Latest filing 2025-11-05 Capital/Financing Update
Country US United States of America
Listing US ORKA

About Oruka Therapeutics, Inc.

https://orukatx.com/

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel biologics for chronic skin diseases and other inflammatory conditions. The company applies advanced antibody engineering to validated modes of action to create potentially best-in-class monoclonal antibodies. Its lead program, ORKA-001, targets the IL-23 cytokine for the treatment of moderate-to-severe plaque psoriasis. Oruka's mission is to redefine the standard of care by developing treatments that achieve high rates of complete disease clearance with a significantly reduced dosing frequency, potentially requiring only one or two doses per year.

Recent filings

Filing Released Lang Actions
PROSPECTUS
Capital/Financing Update Classification · 100% confidence The document is titled 'PROSPECTUS' and is filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It describes an offering of up to $200,000,000 of common stock through a sales agreement with TD Securities (USA) LLC. The text includes details about the sales agreement, the method of sale (at-the-market offering), compensation to the sales agent, risk factors, use of proceeds, dilution, dividend policy, and plan of distribution. It also references the registration statement on Form S-3 and includes forward-looking statements typical of securities offering documents. This is a clear indication that the document is a prospectus related to a capital raising event, specifically an equity offering. According to the filing definitions, updates on company fundraising or financing activities fall under 'Capital/Financing Update' (CAP). The document is not an annual or quarterly report, nor is it a regulatory filing or announcement of a report. It is a detailed disclosure document for a capital raise. Therefore, the correct classification is 'CAP' with high confidence.
2025-11-05 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-18 English
AMENDMENT NO. 1 TO FORM S-3
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 1 to a Form S-3 Registration Statement filed with the SEC by Oruka Therapeutics, Inc. It is a registration statement under the Securities Act of 1933, related to the resale of shares by selling stockholders. The text includes detailed information about the securities being registered, the selling stockholders, and the plan of distribution. This type of filing is a capital markets document related to securities registration and offering, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration statement amendment. Therefore, it fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as registration statements for securities offerings.
2025-10-14 English
AMENDMENT NO. 1 TO FORM S-3
Capital/Financing Update Classification · 100% confidence The document is titled 'Amendment No. 1 to Form S-3' and is a registration statement filed with the SEC under the Securities Act of 1933. It includes a prospectus for the offering of securities up to $500 million, describing common stock, preferred stock, depositary shares, and warrants. The document is a registration statement amendment related to securities offerings, not a financial report, earnings release, or management discussion. Form S-3 is a registration form used for securities offerings, indicating this is a capital raising filing. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, supporting a high confidence classification as CAP.
2025-10-14 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used by companies to register securities for public offering. It includes a base prospectus and a sales agreement prospectus for the offering of common stock, preferred stock, depositary shares, and warrants. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed registration and offering information, not just an announcement or a brief notice.
2025-10-03 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for resale or new offerings. It includes detailed information about the securities being registered, selling stockholders, and the terms of the offering. The document is a registration statement under the Securities Act of 1933, not a financial report, earnings release, or management discussion. It is a capital markets filing related to securities registration and resale. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement or notice, so it is not RPA or RNS. Hence, the classification is CAP with high confidence.
2025-10-03 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.